Supportive care in oncology is a broad term that encompasses indications that are either a symptom of a patient’s cancer or a side effect of cancer treatment. It is a field that has historically been given low priority by physicians, healthcare institutions and pharmaceutical developers alike, and as such, contains various unmet needs.

The figure below presents an overview of the competitive landscapes of six prominent indications within the supportive care in oncology field. Of these six indications, the chemotherapy-induced indications – nausea and vomiting, neutropenia, and anemia – are currently most well-served in terms of available marketed agents.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

However, the marketed landscape for oral mucositis is lacking, while cancer cachexia contains a non-existent market landscape as there are no approved treatments for this condition. As such, those two indications present with the highest level of unmet need, and possess high- and medium-sized late-stage pipeline landscapes, respectively.

Chemotherapy-induced neutropenia also possesses a large pipeline, which contains a large number of biosimilars. Various unmet needs also remain in the remaining indications and present numerous opportunities for developers to enter, or expand their presence within, this field by addressing the gaps in these markets.

Competitive landscape across supportive care indications

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Source: GlobalData. High, medium and low measurements are provided for each indication relative to the other indications. For example, the late-stage pipelines of oral mucositis and chemotherapy-induced neutropenia are large only in relation to the other indications within this table, rather than being large in terms of the overall oncology field. 

Related reports

GlobalData (2017). PharmaFocus: Supportive Care in Oncology, GDHC010PFR